EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis

José Antonio Blázquez-Cabrera iD, Javier Torres-Hernández iD, Roger Bouillon, Antonio Casado-Díaz iD, José Manuel Quesada-Gomez, Laura Navarro-Casado

Nutrients · 2025

DOI: 10.3390/nu17121968 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nutrients, 2025. Verfasst von José Antonio Blázquez-Cabrera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Calcifediol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Complejo Hospitalario Universitario de Albacete, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunomodulatory treatments targeting excessive host immune responses favorably shifting the course of COVID-19. High doses of calcifediol may reduce the mortality of this infection.

Objective

To evaluate how a high dose of calcifediol modifies the risk of death in patients hospitalized with COVID-19 during the first outbreaks.

Design

A retrospective, observational study to evaluate the relationship between treatment with calcifediol and the risk of death in patients hospitalized with COVID-19 at the “Complejo Hospitalario Universitario de Albacete” (CHUA), Spain, during the months of January to March 2021. Patients were treated with corticosteroids, and some patients also received baricitinib and/or high doses of calcifediol, according to CHUA’s therapeutic protocol 2021 for COVID-19. The primary outcome measure was mortality according to calcifediol treatment.

Results

A total of 230 patients were included. 25(OH)D levels were measured on admission in 148 patients, showing a high prevalence of vitamin D deficiency [median 25(OH)D: 17.5 ng/mL]. Thirty-four (23%) had severe deficiency (25(OH)D ≤ 10 ng/mL). In the 119 patients (51.7%) who received in-hospital treatment with a high dose of calcifediol, the mortality rate was 12.6% (15 cases, 95% confidence interval [CI], 7.8–19.8%), while in 111 patients who did not receive treatment with calcifediol, the death rate was 23.4% (26 cases, 95% CI: 16.5–32.1%; p = 0.039). The odds ratio (OR) in treated vs. untreated patients was 0.47 (95% CI: 0.23–0.95). Among the patients admitted with severe deficiency, 16 received treatment with calcifediol, with a mortality rate of 0.0% (0 cases, 95% CI: 0.0–19.4%), while in the 18 not treated with calcifediol, a death rate of 38.9% was observed (7 cases, 95% CI: 20.3–61.4%; p = 0.008). The mortality rate was lower in patients treated with the combination of calcifediol and corticosteroids vs. those treated with corticosteroids alone (p = 0.038) and vs. those treated with corticosteroids and baricitinib (p = 0.033).

Conclusions

In the ALBACOVIDIOL study, calcifediol treatment was associated with a lower observed mortality rate in hospitalized patients with COVID-19 treated with corticosteroids (with or without baricitinib), especially in those with severe vitamin D deficiency. Causality cannot be inferred due to the retrospective study design. (Public database: ClinicalTrials.gov, NCT05819918).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 Drug TreatmentCalcifediolHumansRetrospective StudiesMaleFemaleMiddle AgedAgedSpainHospitalizationVitamin D DeficiencySARS-CoV-2PurinesHospital MortalityAged, 80 and overAdrenal Cortex HormonesSulfonamidesAzetidinesPyrazoles

Stichwörter der Autor:innen

COVID-19SARS-CoV-2VDRbaricitinibcalcifediolcalcitriolcorticoidsdexamethasoneprednisonerespiratory distress syndrome (ARDS)

Substanzen

CalcifediolPurinesAdrenal Cortex HormonesbaricitinibSulfonamidesAzetidinesPyrazoles

Autor:innen und Institutionen

  • Internal Medicine Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain.
  • Clinical Biochemistry Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain.
  • Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat, 3000 Leuven, Belgium.
  • Unidad de Gestión Clínica de Endocrinología y Nutrición-GC17, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
  • CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), 14004 Córdoba, Spain.
  • Departamento de Enfermería, Farmacología y Fisioterapia, Universidad de Córdoba, 14004 Córdoba, Spain.

ORCID-Profile: José Antonio Blázquez-Cabrera, Javier Torres-Hernández, Antonio Casado-Díaz

Förderung

  • Complejo Hospitalario Universitario de Albacete
  • Complejo Hospitalario Universitario de Albacete, Albacete, Spain

Zitieren

APA

Blázquez-Cabrera, J. A., Torres-Hernández, J., Bouillon, R., Casado-Díaz, A., Quesada-Gomez, J. M., & Navarro-Casado, L. (2025). ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis. Nutrients. https://doi.org/10.3390/nu17121968

Vancouver

Blázquez-Cabrera JA, Torres-Hernández J, Bouillon R, Casado-Díaz A, Quesada-Gomez JM, Navarro-Casado L. ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis. Nutrients. 2025. doi:10.3390/nu17121968

BibTeX
@article{BlzquezCabrera2025,
  author = {Blázquez-Cabrera, José Antonio and Torres-Hernández, Javier and Bouillon, Roger and Casado-Díaz, Antonio and Quesada-Gomez, José Manuel and Navarro-Casado, Laura},
  title = {ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17121968}
}
Kostenlos starten →